Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Other hematologic neoplasm 1Lymphoid 1Genitourinary 1Gastrointestinal 1CNS 1Breast 1

Conditions

Glioblastoma 47Brain Neoplasms 24Central Nervous System Neoplasms 22Astrocytoma 16Glioma 15Medulloblastoma 11Neoplasms 8Oligodendroglioma 7Lymphoma 7Recurrence 6Gliosarcoma 6Spinal Cord Neoplasms 2Melanoma 2Lymphoma, Non-Hodgkin 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Lymphoma, AIDS-Related 2Lung Neoplasms 2Leukemia, Myeloid, Acute 2Ependymoma 2Burkitt Lymphoma 2Uveal Melanoma 1Solid Tumor 1Sarcoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Optic Nerve Glioma 1Newly Diagnosed High Grade Glioma 1Neuroectodermal Tumors, Primitive 1Neuroectodermal Tumors 1

Interventions

Fulvestrant 10Everolimus 6Cetuximab 6Alpelisib 6Letrozole 4serabelisib 3ribociclib 3palbociclib 3duvelisib 3berzosertib 3Paclitaxel 3PX-866 3NVP-BKM120 3Irinotecan 3sapanisertib 2pembrolizumab 2parsaclisib 2olaparib 2binimetinib 2Topotecan 2Gemcitabine 2Carboplatin 2volagidemab 1venetoclax 1tivozanib 1tipifarnib 1tanezumab 1talazoparib 1sotorasib 1ruxolitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Hereditary Sensory and Autonomic Neuropathies × Lomustine × Clear all
NCT03678883 2026-04-03

9-ING-41 in Patients With Advanced Cancers

Actuate Therapeutics Inc.

Phase 2 Active not recruiting
350 enrolled
BreastCNSGastrointestinalGenitourinaryLymphoidOther hematologic neoplasmSarcomaThoracic

Bone Neoplasms, Breast Neoplasms, Glioma, Kidney Neoplasms, Lung Neoplasms, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Pancreatic Neoplasms, Sarcoma, Colorectal Neoplasms, Leukemia-Lymphoma, Adult T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡